Wild mountain ginseng, Panax ginseng Meyer, occupies a near-mythical status across Korea, China, and Japan, where it has been harvested for centuries as a medicinal herb and health food. Its value stems from ginsenosides, a family of triterpene saponins that constitute the plant’s primary pharmacological constituents. These compounds are conventionally divided into three structural groups: the protopanaxadiol type, which includes well-studied molecules such as Rb1, Rb2, Rb3, Rd, Rg3, and Rh2; the protopanaxatriol type, encompassing Re, Rf, Rg1, Rg2, and Rh1; and the oleanolic acid type, represented by Ro and related saponins. Decades of research have attributed a remarkable spectrum of biological activities to ginsenosides, including immune enhancement, antioxidant and antibacterial effects, antidiabetic and anti-inflammatory actions, anti-aging properties, and cardioprotective and neuroprotective benefits.

The problem, of course, is supply. A wild mountain ginseng root of this age is an extraordinarily rare resource, and demand for authentic, high-quality material far exceeds what nature can provide. The research team’s strategy was to sidestep the bottleneck entirely by generating adventitious roots, roots that arise from somatic tissue rather than from seed germination, from the 150-year-old specimen, designated 150y-Mg. These cultured roots were then scaled up in 1000-liter industrial bioreactors, where they grew in Murashige and Skoog medium supplemented with 5 percent sucrose by weight and 5 milligrams per liter of indole-3-butyric acid, a synthetic auxin that promotes root growth and ginsenoside accumulation.

The central question was whether the cultured roots could genuinely be considered the same plant. To answer it, the researchers turned to SNP genotyping, a technique that reads single-nucleotide variations scattered across the genome and produces a molecular fingerprint unique to each individual. Using a panel of 192 SNP markers, they compared the original mountain ginseng with two independently analyzed adventitious root samples. The result was unambiguous: 100 percent genotype concordance across the entire panel. Of the 192 loci, 184 were homozygous, meaning both copies of the gene carried the same variant, five were heterozygous, and three produced null calls that could not be scored. Calculated across the 189 callable non-null loci, the genetic fixation rate stood at 97.4 percent, a figure that reflects the high homozygosity typical of a long-lived, likely self-purging lineage rather than any discrepancy between the parent plant and its cultured offspring.

With genetic identity confirmed, the team shifted to the metabolome, the complete inventory of small molecules that defines what a plant actually produces. Liquid chromatography coupled with mass spectrometry, or LC–MS, revealed clear chemical differences among the analyzed materials. Within the sample set examined, malonyl ginsenoside Rb2/Rb3 was detected in the original 150-year-old mountain ginseng but not in cultivated Panax ginseng, whereas ginsenosides XVII and F2 appeared in the bioreactor-grown adventitious roots but were absent from cultivated ginseng under the same analytical conditions. The authors are careful to frame these observations as comparison-specific metabolite features rather than validated authentication markers, a distinction that matters for any future attempt to certify the origin of ginseng products in the marketplace.

That caution is scientifically warranted. A single comparison between one wild specimen and one cultivated reference cannot establish whether a particular metabolite is truly characteristic of age, habitat, or lineage. Environmental conditions, developmental stage, and analytical parameters can all shift the metabolic profile of ginseng tissue. What the LC–MS data do provide is a shortlist of candidate compounds, malonyl ginsenoside Rb2/Rb3, ginsenoside XVII, and ginsenoside F2, that now deserve systematic validation across broader and independent ginseng cohorts before they could ever serve as reliable markers of wild mountain provenance.

Complementing the LC–MS work, high-performance liquid chromatography, or HPLC, quantified the ginsenoside content of the adventitious roots and revealed distinct quantitative patterns that set them apart from conventional material. The relative proportions of individual saponins matter enormously for pharmacological activity, since different ginsenosides act on different molecular targets in the human body. A culture line that skews toward particular saponin classes could, with further optimization, become a standardized source of specific bioactive molecules, something that wild-harvested roots, with their inherent variability, can never guarantee.

The biomedical potential of the bioreactor-grown roots was explored through preliminary in vitro assays. These experiments provided early evidence of two activities of considerable commercial and clinical interest: anti-inflammatory effects and the ability to stimulate the proliferation of dermal papilla cells, the specialized fibroblasts at the base of hair follicles that regulate hair growth. The dermal papilla finding in particular hints at possible applications in cosmetics and hair-loss research, an area where ginseng-derived compounds have long attracted attention. The authors emphasize, however, that these are preliminary results, and the path from a cell-culture assay to a validated therapeutic or cosmetic ingredient involves extensive further testing.

What makes this study notable is not any single result but the complete pipeline it demonstrates. A rare, irreplaceable botanical resource was captured genetically, propagated indefinitely in sterile culture, scaled to industrial volumes, verified as a true genetic match, and profiled chemically and functionally, all without the plant ever leaving the laboratory. The 1000-liter bioreactor scale is the crucial detail here: it transforms what would otherwise be a botanical curiosity into a feasible production platform. Adventitious root culture of ginseng has been explored before, but anchoring the technology to a documented 150-year-old wild genotype, with SNP-level traceability, raises the standard for authenticity in an industry plagued by adulteration and mislabeling.

The researchers are candid about the limits of the current work. The metabolite features they observed are candidates, not conclusions, and the in vitro activities require confirmation in more rigorous models. Yet the foundation they have laid, complete genetic concordance, a reproducible culture system, and a defined chemical baseline, gives the field exactly what it needs to move forward: a stable reference material against which future wild and cultivated ginseng samples can be compared. If subsequent studies validate the candidate markers across independent cohorts, the combination of SNP fingerprinting and LC–MS profiling could become a powerful authentication toolkit. And if the anti-inflammatory and dermal papilla activities hold up, the roots of a plant that took 150 years to grow in the mountains may one day be produced by the ton, its ancient chemistry preserved in stainless steel tanks rather than in vanishing forest soil.

Subject of Research: Metabolomic profiling and bioreactor production of adventitious roots from a 150-year-old wild mountain ginseng

Article Title: Metabolomic profiling and biomedical potential of adventitious roots derived from a 150-year-old mountain ginseng

Article References: Lee, H.-S., Han, J.-E., Kwon, A.-R., Son, E.-J., Park, H., Kim, M.-O., Kim, Y. J., Lee, K. Y., Yang, T.-J., Murthy, H. N., Paek, K.-Y., & Park, S.-Y. (2026). Metabolomic profiling and biomedical potential of adventitious roots derived from a 150-year-old mountain ginseng. BMC Plant Biology. https://doi.org/10.1186/s12870-026-10136-1

Image Credits: AI Generated

DOI: 10.1186/s12870-026-10136-1

Keywords: Panax ginseng, mountain ginseng, ginsenosides, adventitious roots, metabolomics, LC-MS, SNP genotyping, plant biotechnology, bioreactor, anti-inflammatory, dermal papilla cells, BMC Plant Biology

The study, published in Food Science & Nutrition, was framed around the concept of medicine-food homology, a principle embedded in Chinese regulatory practice that classifies certain botanicals, including ginseng, as substances traditionally used as both food and medicine. In China, ginseng is officially listed in the medicine-food homology catalogue, permitting its use as a common food ingredient in soups, teas, beverages, and functional food products. The content of ginsenoside Rb1 in cultivated ginseng varies considerably with growing conditions, ranging from 2.22 to 11.22 milligrams per gram, but its long history of safe dietary exposure is precisely what makes it attractive as a candidate for nutrition-based cancer prevention rather than conventional pharmacology.

To identify the active substance responsible for the anti-pancreatic-cancer effects of a ginseng-containing herbal formula developed by the group, the researchers first applied ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. This profiling step singled out ginsenoside Rb1 as a core bioactive component, prioritized over other ginsenosides such as Rg1, Re, and Rg3 because of its high abundance in ginseng, its favorable safety profile as a food-derived saponin, and its documented antitumor and immunomodulatory activities. The team then deployed a network pharmacology screen, integrating three target-prediction platforms with five pancreatic cancer disease-target databases, to narrow the field of candidate mechanisms.

The computational pipeline was ambitious in scope. It identified 587 candidate targets for ginsenoside Rb1 and 905 pancreatic cancer-related targets, with intersection analysis revealing 110 shared targets. The resulting protein-protein interaction network contained 491 nodes and 3,728 edges, and topology analysis based on degree, betweenness, and closeness centrality surfaced a set of hub genes including STAT3, AKT1, CASP3, BCL2, HIF1A, MTOR, and SRC. KEGG enrichment analysis ultimately locked the PI3K-AKT signaling pathway as the priority candidate for experimental validation, a hypothesis the team then carried into the laboratory.

The in vivo evidence came from an orthotopic pancreatic cancer model established by inoculating KPC-derived cancer cells directly into the pancreas of C57BL/6 mice. Mice were randomly assigned to five groups receiving saline, the chemotherapy drug gemcitabine, or ginsenoside Rb1 at 25, 50, or 100 milligrams per kilogram per day. The results were striking: ginsenoside Rb1 reduced tumor growth in a dose-dependent fashion, with the high-dose group achieving efficacy comparable to gemcitabine. Ki67 staining confirmed reduced tumor cell proliferation, and high-dose treatment prolonged survival without any obvious loss of body weight, a signal that the compound was well tolerated at therapeutic doses.

Metastasis, the process that makes pancreatic cancer so deadly, was also blunted. In a syngeneic liver metastasis model, ginsenoside Rb1 treatment reduced liver metastatic burden, as shown by smaller tumor-invading areas, fewer metastatic lesions on histological staining, and a lower liver-to-body weight ratio. Immunohistochemistry revealed that the compound suppressed the expression of metastasis-related epithelial-mesenchymal transition markers, including Zeb-1 and Vimentin, in the liver lesions. Together with the primary tumor data, these findings suggested that ginsenoside Rb1 acts on more than just the cancer cells themselves.

That suspicion hardened into the study’s central insight when the researchers turned to the tumor microenvironment. Although ginsenoside Rb1 showed only limited direct cytotoxicity against pancreatic cancer cell lines and no toxicity toward normal pancreatic ductal epithelial cells, it produced dramatic changes in the immune landscape of the tumors. Multiplex immunofluorescence revealed that macrophages were a major immune population in pancreatic tumor tissue, and the most notable change after treatment was a dose-dependent reduction in M2-like macrophage markers, including CD206, CD163, and ARG1. Flow cytometry of tumor-infiltrating cells confirmed that ginsenoside Rb1 selectively decreased ARG1-positive CD11b-positive F4/80-positive M2 macrophages while leaving CD86-positive M1 macrophages untouched, indicating a selective suppression of the pro-tumoral polarization program rather than a wholesale depletion of macrophages.

The mechanism was traced to the PI3K-AKT pathway. Western blotting showed that ginsenoside Rb1 reduced phosphorylation of PI3K and AKT in a dose-dependent manner in both tumor tissues and macrophages, and molecular docking with AutoDock Vina suggested stable binding of the compound to AKT1 and PIK3CA with strong binding energies. In cell culture, the team generated M2-like macrophages from both THP-1 cells and human peripheral blood monocytes, and found that ginsenoside Rb1 had minimal effects on unpolarized macrophages but reduced the induction of M2 markers such as CD206, CD115, and TGFB1 in both models. The compound, in other words, appears to intervene at the point where resting macrophages are being converted into tumor-supporting ones.

Functional assays drove the point home. Conditioned medium from ginsenoside Rb1-treated M2-like macrophages reduced the growth of a patient-derived pancreatic tumor organoid compared with medium from untreated M2 macrophages, suggesting that the reprogrammed macrophages had lost much of their tumor-promoting activity. In a complementary in vivo test, KPC-derived pancreatic cancer cells were co-injected with either untreated or ginsenoside Rb1-treated M2-like macrophages into C57BL/6 mice, and the co-injection of treated macrophages was associated with reduced metastatic burden. Safety evaluations reinforced the compound’s tolerability: major organs showed no gross abnormalities, serum markers of liver and kidney function, including ALT, AST, BUN, creatinine, and uric acid, remained unchanged, and hepatic expression of pro-inflammatory cytokines such as TNF-alpha, IFN-gamma, and IL-6 was not significantly altered.

The authors are careful about the limits of their evidence. The study does not establish definitive causality between PI3K-AKT inhibition and macrophage modulation, which would require pathway rescue or genetic gain-of-function experiments. Tumor-associated macrophage characterization relied on conventional M2-associated markers that cannot fully resolve the heterogeneity of these cells in pancreatic cancer, and only one patient-derived organoid line was used, so inter-patient variability remains untested. Critically, the compound was administered intraperitoneally, meaning that oral bioavailability, gut microbiota-mediated deglycosylation to compound K, food-matrix effects, and processing stability all require separate investigation before ginsenoside Rb1 can be developed as a functional food ingredient or nutritional adjuvant. Standardization, toxicological evaluation, and GRAS determination also lie ahead. Still, the work offers a compelling proof of concept: a dietary botanical constituent with centuries of safe human consumption can engage tumor-immune signaling in a way that is compatible with long-term nutritional intervention, opening a preventive, low-toxicity avenue against one of medicine’s most intractable cancers.

Subject of Research: Ginsenoside Rb1 from Panax ginseng reprograms tumor-associated macrophages via PI3K-AKT signaling to suppress pancreatic cancer progression

Article Title: Ginsenoside Rb1 From the Functional Food Panax ginseng Suppresses Pancreatic Cancer Progression via Macrophage Reprogramming Through the PI3K‐AKT Pathway

Article References: Dong, C.-S., Wang, G., Niu, Y., Sun, X., Ren, W., Zhang, J., Zhang, Y., Wu, R.-X., & Wu, X. (2026). Ginsenoside Rb1 From the Functional Food Panax ginseng Suppresses Pancreatic Cancer Progression via Macrophage Reprogramming Through the PI3K ‐ AKT Pathway. Food Science & Nutrition, 14(10), Article e72468. https://doi.org/10.1002/fsn3.72468

Image Credits: AI Generated

DOI: 10.1002/fsn3.72468

Keywords: ginsenoside Rb1, Panax ginseng, pancreatic cancer, macrophage polarization, PI3K-AKT pathway, tumor microenvironment, medicine-food homology, functional food, liver metastasis, network pharmacology, immunomodulation, patient-derived organoids

The research team set out to answer a deceptively simple question: if PM2.5 can disrupt the gut, can a well-characterized botanical extract counteract that disruption? PM2.5 refers to particles smaller than 2.5 micrometers in diameter, fine enough to penetrate deep into the body. While inhalation is the obvious exposure route, epidemiological studies, including earlier work linking air pollutant exposure to inflammatory bowel disease visits, suggest these particles exert systemic effects that reach the gastrointestinal tract. Animal studies have shown that chronic PM2.5 exposure can degrade the intestinal barrier, trigger inflammatory signaling cascades, and destabilize the gut microbiome, the dense community of microbes that performs critical metabolic and immune functions.

Korean red ginseng was chosen for its rich arsenal of ginsenosides, steroidal saponins with documented antioxidant and anti-inflammatory properties. Before any animal experimentation, the researchers chemically characterized their KRG extract using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry, or UPLC-Q-TOF/MS2. This analytical technique allowed the team to profile the ginsenoside composition of the extract precisely, a crucial step in phytochemical research where biological activity depends heavily on the exact mixture of compounds present. Steaming fresh ginseng roots transforms their ginsenoside profile, generating less polar and often more bioavailable forms that are believed to account for red ginseng’s distinctive pharmacological activity.

With the extract characterized, the team orally administered it to mice subjected to PM2.5 exposure for twelve weeks, a duration long enough to model chronic, real-world exposure rather than an acute insult. The results, reported across four sets of experiments described in the paper, paint a coherent picture of protection operating at multiple biological levels simultaneously: oxidative stress, barrier integrity, inflammatory signaling, and microbial ecology.

The first line of defense the researchers examined was oxidative stress. PM2.5 particles carry reactive surfaces and redox-active metals that generate free radicals in tissue, overwhelming cellular antioxidant systems. In the large intestine of PM2.5-exposed mice, the team measured elevated levels of malondialdehyde, a canonical marker of lipid peroxidation and oxidative damage to cell membranes. KRG supplementation significantly reduced malondialdehyde levels, indicating less membrane damage. Just as importantly, the extract restored the animals’ own antioxidant machinery: levels of reduced glutathione, the intestine’s principal endogenous antioxidant, rebounded, and the activity of superoxide dismutase, the enzyme that disarms superoxide radicals, recovered toward normal. This dual effect, dampening damage while replenishing defenses, suggests KRG acts not as a simple radical scavenger but as a modulator of the cellular redox system.

Perhaps the most consequential finding concerns the intestinal barrier itself. The gut lining is a single layer of epithelial cells sealed together by protein complexes called tight junctions, which include zonula occludens-1 (ZO-1), occludin, and claudin-1. These molecular stitches prevent the unregulated passage of bacteria, toxins, and food antigens into underlying tissue. When tight junctions fail, the resulting ‘leaky gut’ is thought to fuel chronic systemic inflammation and has been implicated in disorders ranging from inflammatory bowel disease to metabolic syndrome. In the PM2.5-exposed mice, expression of these tight junction proteins was compromised; in the mice that also received KRG, ZO-1, occludin, and claudin-1 were preserved, keeping the physical seal of the gut intact despite the ongoing pollutant assault.

Downstream of barrier defense lies inflammatory signaling, and here the study identified a specific molecular pathway through which KRG exerts its effect. The researchers found that KRG suppressed activation of the TLR-4/NF-κB axis. TLR-4 is a pattern-recognition receptor on immune and epithelial cells that, when triggered by damage-associated molecular signals, initiates a signaling cascade culminating in the activation of NF-κB, a transcription factor that switches on genes encoding pro-inflammatory cytokines. Chronic NF-κB activation in the intestine drives the sustained inflammation characteristic of pollutant-induced tissue injury. By quieting this pathway, KRG appears to interrupt the chain reaction that converts particle-induced cellular stress into full-blown intestinal inflammation. This mechanism aligns with previous work from the same group showing that ginseng preparations can temper systemic inflammation in PM2.5-exposed mice, as well as with broader literature on ginsenosides’ immunomodulatory properties.

The fourth and perhaps most novel dimension of the study is the gut microbiota. Using microbiome analysis, the team showed that PM2.5 exposure disrupted the composition of the gut microbial community, and that KRG supplementation shifted the community back toward a healthier state, increasing the abundance of beneficial bacterial taxa. Alongside this compositional recovery, the researchers measured fecal short-chain fatty acids, the metabolites that fermenting gut bacteria produce from dietary fiber. SCFAs such as butyrate and propionate are not mere metabolic byproducts; they nourish colonocytes, reinforce tight junctions, and exert regulatory effects on the immune system. PM2.5 exposure depleted fecal SCFA levels in the mice, but KRG restored them.

Crucially, the team did not stop at cataloging individual effects. Through correlation analysis, they linked the pieces together, finding associations between microbial recovery, short-chain fatty acid levels, barrier integrity, and inflammatory status. This integrative view suggests a mechanistic model in which KRG supports the gut microbial ecosystem, which in turn produces more SCFAs, which in turn fortify the epithelial barrier and dampen TLR-4/NF-κB-driven inflammation, breaking the vicious cycle by which pollution-induced dysbiosis and intestinal injury reinforce one another. The ginseng root, in this framing, functions less like a single-target drug and more like an ecosystem engineer, nudging an entire interconnected system back toward equilibrium.

The findings arrive amid rising global concern about air quality. PM2.5 exposure is responsible for millions of premature deaths annually, and populations in rapidly industrializing regions face chronic exposure that regulatory measures alone cannot immediately eliminate. While this study was conducted in mice and its results cannot be directly translated into dietary recommendations for humans, it strengthens the scientific rationale for examining foods and botanicals as adjunctive protections against environmental stressors. Previous work by the same research group found that Korean red ginseng prevented deterioration of lung and brain function in chronically PM2.5-exposed mice by regulating systemic inflammation, and other laboratories have reported similar gut-protective effects for plant-derived compounds such as black tea polyphenols. Together, these studies sketch an emerging field sometimes described as nutritional resilience against pollution: the idea that diet can meaningfully modulate how the body responds to unavoidable environmental exposures.

The authors caution, as all rigorous researchers must, that mouse models have limits and that dosing, bioavailability, and long-term safety in humans remain open questions. Yet the convergence of evidence across oxidative stress, barrier biology, inflammatory signaling, and microbiome science in a single, well-controlled animal study is notable. Korean red ginseng, a food with centuries of traditional use and a substantial modern research literature, now has a documented, mechanistically grounded case for protecting one of the body’s most vulnerable interfaces with the outside world from one of modernity’s most pervasive pollutants. As researchers continue to dissect the gut-lung axis and the microbiome’s role in environmental disease, studies like this one suggest that the pharmacy of the future for pollution defense may already be sitting on the dinner table, waiting to be validated one carefully characterized extract at a time.

Subject of Research: Protective effects of Korean red ginseng against PM2.5-induced intestinal damage via inflammatory signaling and gut microbiota regulation in mice

Article Title: Korean red ginseng (Panax ginseng Meyer) mitigates PM2.5-induced intestinal damage through regulation of inflammatory signaling and gut microbiota

Article References: Lee, H. L., Kim, J. H., Kim, J. M., Lee, H. S., Choi, H. J., & Heo, H. J. (2026). Korean red ginseng (Panax ginseng Meyer) mitigates PM2.5-induced intestinal damage through regulation of inflammatory signaling and gut microbiota. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02306-6

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02306-6

Keywords: Korean red ginseng, Panax ginseng, PM2.5, intestinal barrier, tight junctions, TLR-4, NF-κB, gut microbiota, short-chain fatty acids, oxidative stress, ginsenosides, air pollution